MX2021007213A - Composicion terapeutica de lidocaina intranasal. - Google Patents
Composicion terapeutica de lidocaina intranasal.Info
- Publication number
- MX2021007213A MX2021007213A MX2021007213A MX2021007213A MX2021007213A MX 2021007213 A MX2021007213 A MX 2021007213A MX 2021007213 A MX2021007213 A MX 2021007213A MX 2021007213 A MX2021007213 A MX 2021007213A MX 2021007213 A MX2021007213 A MX 2021007213A
- Authority
- MX
- Mexico
- Prior art keywords
- spray formulation
- nasal spray
- dose
- nasal
- sodium channel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0618—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe una formulación de pulverización nasal y un método de uso de un bloqueador de los canales de sodio de acción local para tratar el dolor, en donde la formulación de pulverización nasal comprende de aproximadamente 5 % a aproximadamente 30 % p/v de un bloqueador de los canales de sodio localmente activo, de aproximadamente 0.25 % a aproximadamente 5 % p/v de un agente tampón y de aproximadamente 5 a aproximadamente 99 % p/v de un portador farmacéuticamente aceptable para la administración nasal. La formulación de pulverización nasal está contenida preferentemente en un pulverizador mecánico de dosis múltiples que pulveriza una dosis unitaria de la formulación de pulverización nasal con una pluma ancha y un tamaño de gota pequeño, de manera que la dosis unitaria se administra mediante el accionamiento del dispositivo pulverizador mecánico de dosis múltiples y pulverización de un volumen de la formulación de pulverización nasal en cada orificio nasal de un sujeto humano. Preferentemente, la formulación de pulverización nasal no incluye un conservante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781969P | 2018-12-19 | 2018-12-19 | |
| PCT/US2019/064472 WO2020131380A1 (en) | 2018-12-19 | 2019-12-04 | Therapeutic composition of intranasal lidocaine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007213A true MX2021007213A (es) | 2021-09-23 |
Family
ID=71098283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007213A MX2021007213A (es) | 2018-12-19 | 2019-12-04 | Composicion terapeutica de lidocaina intranasal. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11857520B2 (es) |
| EP (1) | EP3897603A4 (es) |
| JP (1) | JP2023502282A (es) |
| KR (1) | KR20210106503A (es) |
| CN (1) | CN113573705A (es) |
| AU (1) | AU2019403903A1 (es) |
| CA (1) | CA3122363A1 (es) |
| EA (1) | EA202191506A1 (es) |
| MX (1) | MX2021007213A (es) |
| WO (1) | WO2020131380A1 (es) |
| ZA (1) | ZA202105035B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022061443A1 (en) * | 2020-09-24 | 2022-03-31 | Rhinoclear Nasal Care Solutions Inc. | Analgesic nose plugs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE431092B (sv) | 1979-07-10 | 1984-01-16 | Thuresson Af Ekenstam Bo | Terapeutiskt aktiva, substituerade piperidinkarboxianilider |
| US5008289A (en) * | 1988-12-02 | 1991-04-16 | Galenpharma, Inc. | Composition for treating nasal disorders and headaches |
| US6491940B1 (en) * | 1999-01-27 | 2002-12-10 | Bruce H. Levin | Apparatus for administering composition for inhibiting cerebral neurovascular disorders and muscular headaches |
| US6432986B2 (en) * | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| ATE335482T1 (de) | 1999-06-10 | 2006-09-15 | Bridge Pharma Inc | Dermale anästhetika |
| US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
| WO2005023274A1 (en) | 2003-09-05 | 2005-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| PL2522365T3 (pl) * | 2004-11-24 | 2017-05-31 | Meda Pharmaceuticals Inc. | Kompozycje zawierające azelastynę i sposoby ich zastosowania |
| DE102006008874B4 (de) | 2006-02-21 | 2012-06-21 | Ing. Erich Pfeiffer Gmbh | Dosiervorrichtung mit einer manuell betätigbaren Pumpeinrichtung |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| JP2011518881A (ja) | 2008-04-28 | 2011-06-30 | ゾゲニクス インコーポレーティッド | 片頭痛の治療のための製剤 |
| MX2010013484A (es) * | 2008-06-13 | 2011-03-29 | Roxro Pharma Inc Star | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. |
| PL2413899T3 (pl) | 2009-04-03 | 2021-09-20 | St. Renatus, Llc | Dentystyczny środek znieczulający zawierający tetrakainę i środek zwężający naczynia krwionośne do podawania donosowego |
| PL4104848T3 (pl) * | 2009-06-18 | 2024-03-25 | Acerus Pharmaceuticals USA, LLC | Bezpieczne podawanie desmopresyny |
-
2019
- 2019-12-04 WO PCT/US2019/064472 patent/WO2020131380A1/en unknown
- 2019-12-04 CA CA3122363A patent/CA3122363A1/en active Pending
- 2019-12-04 JP JP2021535125A patent/JP2023502282A/ja active Pending
- 2019-12-04 EA EA202191506A patent/EA202191506A1/ru unknown
- 2019-12-04 MX MX2021007213A patent/MX2021007213A/es unknown
- 2019-12-04 EP EP19900739.4A patent/EP3897603A4/en active Pending
- 2019-12-04 US US16/703,444 patent/US11857520B2/en active Active
- 2019-12-04 CN CN201980089576.0A patent/CN113573705A/zh active Pending
- 2019-12-04 AU AU2019403903A patent/AU2019403903A1/en active Pending
- 2019-12-04 KR KR1020217022494A patent/KR20210106503A/ko unknown
-
2021
- 2021-07-16 ZA ZA2021/05035A patent/ZA202105035B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202191506A1 (ru) | 2021-10-08 |
| CN113573705A (zh) | 2021-10-29 |
| EP3897603A1 (en) | 2021-10-27 |
| WO2020131380A1 (en) | 2020-06-25 |
| EP3897603A4 (en) | 2022-09-14 |
| US11857520B2 (en) | 2024-01-02 |
| AU2019403903A1 (en) | 2021-06-24 |
| US20200197338A1 (en) | 2020-06-25 |
| JP2023502282A (ja) | 2023-01-24 |
| ZA202105035B (en) | 2022-03-30 |
| KR20210106503A (ko) | 2021-08-30 |
| CA3122363A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2332405T3 (es) | Una composicion de nicotina liquida tamponada para administracion pulmonar. | |
| WO2001036018A3 (en) | Method and apparatus for relieving ailments using gases to increase the effectiveness of drugs | |
| WO2020086759A3 (en) | Composition and method for treating the lungs | |
| CA2648553A1 (en) | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation | |
| RU2014128343A (ru) | Интраназальные композиции дексмедетомидина и способы их применения | |
| RU2012133969A (ru) | Локальные трансдермальные композиции дексмедетомидина и способы их применения | |
| AU2002315332A1 (en) | Device and method for delivering microdoses of agent to the ear | |
| JP2015513309A5 (es) | ||
| EA201992862A1 (ru) | Назальные лекарственные формы дигидроэрготамина | |
| HK1176318A1 (en) | Injection device | |
| RU2019118647A (ru) | Композиции с кариофилленом, устройства для их введения и способы их использования | |
| AU2017312811A8 (en) | Liquid naloxone spray | |
| MX2021007213A (es) | Composicion terapeutica de lidocaina intranasal. | |
| EA202091199A1 (ru) | Лекарственное средство для предотвращения или лечения риновирусной инфекции | |
| MX2007010886A (es) | Metodos y formulaciones de acarbosa para tratar constipacion cronica. | |
| WO2019136306A8 (en) | Intranasal delivery of levodopa powder by precision olfactory device | |
| MY137249A (en) | Aerosol formulation for inhalation containing a tiotropium salt | |
| RU2010129409A (ru) | Способ лечения псороптоза кроликов и отодектоза плотоядных животных | |
| RU2016152090A (ru) | Интраназальное введение | |
| MX2010013484A (es) | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. | |
| CL2021001755A1 (es) | Dispositivo de administración de fármaco nasal | |
| MY196333A (en) | Intranasal Composition Comprising Betahistine | |
| US20170224936A1 (en) | Nasal treatment delivery device with carbon dioxide and saline, and methods | |
| CA3152988A1 (en) | Oxytocin compositions for treatment of tinnitus | |
| WO2009062193A3 (en) | Methods for administering corticosteroid formulations |